BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38141281)

  • 21. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
    Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
    Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
    Zhang YK; Wang YJ; Lei ZN; Zhang GN; Zhang XY; Wang DS; Al-Rihani SB; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
    Cancer Lett; 2019 Feb; 442():104-112. PubMed ID: 30392788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversal of drug resistance by JS-K and nitric oxide in ABCB1- and ABCG2-expressing multi-drug resistant human tumor cells.
    Sinha BK; Perera L; Cannon RE
    Biomed Pharmacother; 2019 Dec; 120():109468. PubMed ID: 31605952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins.
    Herraez E; Gonzalez-Sanchez E; Vaquero J; Romero MR; Serrano MA; Marin JJ; Briz O
    Mol Pharm; 2012 Sep; 9(9):2565-76. PubMed ID: 22800197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.
    Gupta A; Dai Y; Vethanayagam RR; Hebert MF; Thummel KE; Unadkat JD; Ross DD; Mao Q
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):374-83. PubMed ID: 16404634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy.
    Lozano E; Macias RIR; Monte MJ; Asensio M; Del Carmen S; Sanchez-Vicente L; Alonso-Peña M; Al-Abdulla R; Munoz-Garrido P; Satriano L; O'Rourke CJ; Banales JM; Avila MA; Martinez-Chantar ML; Andersen JB; Briz O; Marin JJG
    Hepatology; 2019 Oct; 70(4):1246-1261. PubMed ID: 30972782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.
    Shepard RL; Cao J; Starling JJ; Dantzig AH
    Int J Cancer; 2003 Jan; 103(1):121-5. PubMed ID: 12455064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp.
    Zhang Y; Laterra J; Pomper MG
    Neoplasia; 2009 Jan; 11(1):96-101. PubMed ID: 19107236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer.
    Yoh K; Ishii G; Yokose T; Minegishi Y; Tsuta K; Goto K; Nishiwaki Y; Kodama T; Suga M; Ochiai A
    Clin Cancer Res; 2004 Mar; 10(5):1691-7. PubMed ID: 15014021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines.
    Elahian F; Kalalinia F; Behravan J
    Drug Chem Toxicol; 2010 Apr; 33(2):113-9. PubMed ID: 20307139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells.
    Ma Y; Wink M
    Phytother Res; 2010 Jan; 24(1):146-9. PubMed ID: 19548284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of the breast cancer resistance protein (ABCG2) in drug transport.
    Mao Q; Unadkat JD
    AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
    Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
    Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
    Zhang YH; Li G; Yu J; Xu MS; Liu ZX
    Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of SN38-resistant T47D breast cancer cell sublines overexpressing BCRP, MRP1, MRP2, MRP3, and MRP4.
    Lee HJ; Choi CH
    BMC Cancer; 2022 Apr; 22(1):446. PubMed ID: 35461219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation.
    Jaramillo AC; Cloos J; Lemos C; Stam RW; Kaspers GJL; Jansen G; Peters GJ
    Leuk Res; 2019 Apr; 79():45-51. PubMed ID: 30849662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.